Section Arrow
INM.NASDAQ
- InMed Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2024/05/16 13:20 EDT
Last
 0.28035
+0.006356 (+2.32%)
Day High 
0.2924 
Prev. Close
0.273994 
1-M High
0.337 
Volume 
174.19K 
Bid
0.2707
Ask
0.29
Day Low
0.262 
Open
0.27 
1-M Low
0.227503 
Market Cap 
1.66M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.27 
20-SMA 0.27 
50-SMA 0.32 
52-W High 2.08 
52-W Low 0.227503 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.42/-21.39
Enterprise Value
1.68M
Balance Sheet
Book Value Per Share
2.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.14M
Operating Revenue Per Share
0.68
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1048+0.0271+34.88%-- 
DNAGinkgo Bioworks Holdings0.8399+0.0008+0.10%-- 
JAGXJaguar Health0.285+0.0299+11.72%-- 
NBYNovaBay Pharmaceuticals0.1188+0.0143+13.68%-- 
NVAXNovavax13.23+0.33+2.56%-- 
Quotes are at least 15-min delayed:2024/05/16 13:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.